Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2564-2569

  Saxman, Scott B ^a   Propert, Kathleen J ^a   Einhorn, Lawrence H ^a   Crawford, E David ^a   Tannock, Ian ^a   Raghavan, Derek ^a   Loehrer, Patrick J ^a   Trump, Donald ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT CARCINOMA; UROGENITAL TRACT TUMOR; UROTHELIUM;

EID: 0030794516     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2564     Document Type: Article

References (15)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA 47:5-27, 1997
2. Sternberg C, Yagoda A, Scher H, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985
3. Sternberg C, Yagoda A, Scher H, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
4. Connor J, Olsson C, Benson M, et al: Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern. Urology 34:353-356, 1989
5. Igawa M, Urakami S, Shiina H, et al: Long-term results with M-VAC for advanced urothelial cancer: High relapse rate and low survival in patients with a complete response. Br J Urol 76:321-324, 1995
6. Loehrer P, Einhorn L, Elson P, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
7. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
9. Cox D: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
10. Logothetis C, Dexeus F, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
11. Logothetis C, Dexeus F, Sella A, et al: Escalated therapy for refractory urothelial tumors: Methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82:667-672, 1990
12. Logothetis C, Finn L, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
13. Loehrer P, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
14. Sternberg C, de Mulder P, van Oosterom A, et al: Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 4:403-407, 1993
15. Seidman A, Scher H, Gabrilove J, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993